Ma, Cynthia X.
Reinert, Tomás
Chmielewska, Izabela
Ellis, Matthew J.
Article History
First Online: 24 April 2015
Competing interests
: M.J.E. receives royalties for patent licensing to Nanostring for sales of the breast cancer prognostic test “Prosigna” and has stock in Bioclassifer LLC that advises Nanostring on Prosigna development. He is also paid as an ad hoc consultant for Novartis, Pfizer and AstraZeneca. C.X.M., T.R. and I.C. declare no competing interests.